2012-10-06 19:12:21 - Fast Market Research recommends "Psoriatic Arthritis - Pipeline Review, H2 2012" from Global Markets Direct, now available
Global Markets Direct's, 'Psoriatic Arthritis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis. Psoriatic Arthritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/468458_psoriatic_arthritis_pipeline_review_h ..
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
* A snapshot of the global therapeutic scenario for Psoriatic Arthritis.
* A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Psoriatic Arthritis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Psoriatic Arthritis Overview
An Overview of Pipeline Products for Psoriatic Arthritis
Psoriatic Arthritis Therapeutics under Development by Companies
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Pre-Clinical Stage Products
Psoriatic Arthritis Therapeutics - Products under Development by Companies
Companies Involved in Psoriatic Arthritis Therapeutics Development
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Protalix BioTherapeutics, Inc.
Alder Biopharmaceuticals Inc.
Centocor Ortho Biotech, Inc.
Psoriatic Arthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Psoriatic Arthritis Therapeutics - Discontinued Products
Psoriatic Arthritis Therapeutics - Dormant Products
Psoriatic Arthritis - Product Development Milestones
Featured News & Press Releases
Jul 26, 2012: Horizon Pharma Announces FDA Approval Of RAYOS Tablets For Rheumatoid Arthritis And Multiple Additional Indications
Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Abbott's Humira
Jul 12, 2012: Celgene's Apremilast Achieves Statistical Significance For Primary Endpoint Of First Phase III Study In Patients With Psoriatic Arthritis
Jun 21, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Enbrel
Jun 06, 2012: UCB Presents Results From RAPID-PsA Study Of Certolizumab Pegol At EULAR Annual European Congress Of Rheumatology
Jun 05, 2012: Janssen Reports Positive Data From Phase III Study Of STELARA For Treatment Of Psoriatic Arthritis At EULAR Annual Congress
Feb 16, 2012: UCB Announces Positive Top-Line Results For Cimzia In Psoriatic Arthritis
Sep 09, 2011: Janssen Biotech Receives Complete Response Letter For SIMPONI Supplemental Biologics License Application
May 25, 2011: Amgen And Pfizer Announce New Results From Multiple Studies Of ENBREL
Apr 26, 2011: NICE Recommends Golimumab For Treatment Of Psoriatic Arthritis
Expert Panel Validation
List of Tables
Number of Products Under Development for Psoriatic Arthritis, H2 2012
Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
F. Hoffmann-La Roche Ltd., H2 2012
Amgen Inc., H2 2012
Eli Lilly and Company, H2 2012
Celltrion, Inc., H2 2012
Pfizer Inc., H2 2012
UCB Group, H2 2012
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.